Sugi Predict

Sugi Predict / Compounds / SCHEMBL375102

SCHEMBL375102

SCHEMBL375102

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)OP(=O)(O)O)[C@@H](O)[C@H]1OP(=O)(O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 7/20 0.61
▸ ADORA1 P30542 2/20 0.61
▸ DNPH1 O43598 1/20 0.56
▸ PRKAB2 O43741 1/20 0.56
▸ TRPM2 O94759 1/20 0.56
▸ LDHA P00338 1/20 0.56
▸ ADRB2 P07550 1/20 0.56
▸ FBP1 P09467 1/20 0.56
▸ SRC P12931 1/20 0.56
▸ P2RY2 P41231 1/20 0.56
▸ P2RY1 P47900 1/20 0.56
▸ PRKAG1 P54619 1/20 0.56
▸ PRKAA2 P54646 1/20 0.56
▸ PDE4D Q08499 1/20 0.56
▸ KCNH2 Q12809 1/20 0.56
▸ PRKAA1 Q13131 1/20 0.56
▸ PDE3A Q14432 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ TAS1R3 Q7RTX0 1/20 0.56
▸ TAS1R1 Q7RTX1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1526121 0.93 P2RY1 (0.66) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL5513986 0.92 RNASEL (0.51) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL32662848 0.92 RNASEL (0.68) RNASELADORA1SRCP2RY2P2RY1
SCHEMBL1122709 0.92 RNASEL (0.66) RNASELADORA1
SCHEMBL4329344 0.92 RNASEL (0.55) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL23752269 0.89 ADORA1 (0.70) RNASELADORA1P2RX1P2RX3P2RX2
SCHEMBL19260795 0.86 P2RY1 (0.66) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL3281799 0.86 ADORA1 (0.61) RNASELADORA1DNPH1PRKAB2TRPM2
Adenosine Phosphate SCHEMBL2828289 0.85 P2RY1 (0.76) RNASELADORA1DNPH1PRKAB2TRPM2
SCHEMBL8508626 0.85 P2RY1 (0.63) RNASELADORA1DNPH1PRKAB2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 — — EP disclosed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 — — WO disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 — — WO disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 — — EP disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 — — US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 — — US disclosed
US-20200278346-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ADJACENT ACQUISITION CO., LLC 2020-09-03 — — US disclosed
EP-3681504-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE Icagen, Inc. (US) 2020-07-22 — — EP disclosed
WO-2019055754-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN, INC. (US) 2019-03-21 — — WO disclosed
US-20150309021-A1 Advanced Drug Development and Manufacturing LOS ALAMOS NATIONAL SECURITY, LLC 2015-10-29 — — US disclosed
US-20070042030-A1 Preparation for the application of agents in mini-droplets IDEA AG (DE) 2007-02-22 — — US disclosed
US-20060264398-A1 Purinergic modulation of smell NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-11-23 — — US disclosed
EP-1624753-A2 PURINERGIC MODULATION OF SMELL The University of Utah Research Foundation (US) 2006-02-15 — — EP disclosed
EP-0475160-B2 Preparation for drug application in minute droplet form IDEA AG (DE) 2004-07-14 — — EP disclosed
WO-2004047749-A2 PURINERGIC MODULATION OF SMELL UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2004-06-10 — — WO disclosed
US-6165500-A Preparation for the application of agents in mini-droplets IDEA AG (DE) 2000-12-26 — — US disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 — — EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 — — EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 — — WO disclosed
US-4151349-A Crystalline potassium salt of β-nicotinamide adenine dinucleotide phosphoric acid and method for its preparation BOEHRINGER MANNHEIM GMBH (DE) 1979-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264398-A1 Purinergic modulation of smell P2RX5, P2RX3, P2RX6 RNASEL 1438/4885ADORA1 78/4885DNPH1 1884/4885
US-20070042030-A1 Preparation for the application of agents in mini-droplets FABP4, NPC1L1, LIPA RNASEL 4347/4885ADORA1 1856/4885DNPH1 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.